Trump Admin Delays Next Steps For Int’l Pricing Index, Rebate Rule

The Trump administration’s spring regulatory agenda , released Wednesday (May 22), shows that two of HHS’ most disruptive drug-pricing regulatory actions -- its proposal to base Medicare Part B pay rates on foreign drug prices and its overhaul of the rebate system -- are set to be released later than originally anticipated. November is the new estimated release window for CMS’ final rule to require that rebates be passed through to consumers in Medicare Part D and Medicaid managed...